Kansas City, KS. – (May 2016) KCAS Bioanalytical and Biomarker Services, a leading bioanalytical and biomarker contract research organization (CRO) has welcomed Abu Siddiqui, Ph.D., as Director, Large Molecule & Biomarker Bioanalysis.
Dr. Siddiqui has more than 15 years experiences designing, managing and executing biologics, vaccine and translational biomarker discovery studies for preclinical and clinical safety programs. “We’ve seen significant demand for, and we are investing heavily in our biologics group, both in strategic new hires and acquisition of state-of-the-art instrument platforms. Our message is clear: we have what our clients and future clients need and we are prepared for the continued evolution of the industry.” states Michael Lanman, Vice President of Operations and acting CEO.
During his career, Dr. Siddiqui has worked as a principal investigator to support large molecule and vaccine preclinical and clinical studies for Johnson & Johnson, Merck and GSK, responsible for both the technical aspects and the regulatory compliance of the bioanalytical assays. Prior to his industry career, Dr. Siddiqui received his Ph.D. from Stockholm University then continued his Post-Doctoral research training at both New York University and Stanford University.
“Our clients trust us to help them navigate through the complex nature of regulated PK bioanalysis, immunogenicity, and biomarker analysis. Dr. Siddiqui’s leadership in biologics, vaccine, and biomarker research will contribute immensely to our mission” states Lanman.
About KCAS Bioanalytical Services
KCAS Bioanalytical & Biomarker Services is a contract laboratory with 36+ years of bioanalytical expertise. Centrally located in Kansas City, KCAS provides small- and large-molecule PK, immunogenicity, and biomarker analysis operating a variety of equipment platforms to service a wide range of therapeutic areas. KCAS’ team leverages a highly scientific staff with an average tenure of 14 years at the company to provide clients of all sizes with expertise in robust assay development, validation, and sample analysis under non-GLP, GLP, and GCP conditions for discovery, preclinical and clinical studies. Our teams have developed and validated more than 5,500 bioanalytical assays and have undergone 15 FDA inspections. Recently KCAS registered for Clinical Laboratory Improvement Amendments (CLIA) certification. Learn more at: www.kcasbio.com